Linagliptin Mylan

Linagliptin, the active ingredient in Linagliptin Mylan, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycemic control when used with diet and exercise.

GNH USA supplies Linagliptin Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Distribution is managed through reliable logistics networks.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance. - Type 2 diabetes mellitus (monotherapy): improves overall glycemic control as an initial oral agent. - Type 2 diabetes mellitus (add‑on therapy): enhances glucose lowering when combined with metformin or other oral agents. - Type 2 diabetes mellitus (in combination with insulin): helps reduce post‑prandial glucose excursions while minimizing insulin dose.

Adverse reactions reported with linagliptin span a range from mild to serious.

Common Side Effects: - Nasopharyngitis: inflammation of the nose and throat. - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms such as cough and congestion. - Dizziness: transient episodes of light‑headedness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: including angioedema and anaphylaxis. - Hepatic injury: marked increase in liver transaminases. - Bullous pemphigoid: autoimmune skin blistering disorder. - Severe hypoglycaemia: when used with insulin or sulfonylureas.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: assess kidney function; dose adjustment is not required but monitor closely. - Hepatic impairment: evaluate liver enzymes; use with caution in moderate to severe disease. - Cardiovascular disease: consider risk‑benefit in patients with heart failure. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose levels. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness. - Insulin or sulfonylureas: combined use can cause severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may lower drug levels, requiring glycaemic monitoring. - Diuretics (thiazides): potential impact on glucose control. - Warfarin: monitor INR as linagliptin may affect anticoagulation. - Digoxin: observe for possible increased serum concentrations.